IMRX
Immuneering Corp - Class A
NASDAQ · Biotechnology
$4.93
+0.41 (+9.07%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 183.49M | 183.65M | 175.87M |
| Net Income | 12.93M | 12.84M | 10.17M |
| EPS | — | — | — |
| Profit Margin | 7.1% | 7.0% | 5.8% |
| Rev Growth | -6.7% | +18.5% | +10.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 68.39M | 72.44M | 69.23M |
| Total Equity | 187.55M | 163.29M | 197.36M |
| D/E Ratio | 0.36 | 0.44 | 0.35 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 22.71M | 20.96M | 19.85M |
| Free Cash Flow | 10.88M | 9.00M | 9.93M |